New drug treatment drug treatment
About Epilepsy Epilepsy is a medical condition that produces seizures that affect a variety of mental and physical functions. A patient is considered to have epilepsy after two or more unprovoked seizures, which occur when a brief, strong surge of new drug treatment drug treatment activity affects part or all of the brain.
An individual may experience various symptoms, from convulsions and loss of consciousness, to some that are not always recognized as seizures, such as blank staring, lip smacking, or jerking movements of arms and legs. Epilepsy can develop at any age and 0.
It has been reported that epilepsy affects nearly 1 million people in Japan, 2. Epilepsy and AMPA Receptor Antagonists Research suggests that the underlying mechanisms of epilepsy involve the overexcitement of neurons caused by the excitatory neurotransmitter glutamate.
The excessive influx of calcium ions into the neurons that occurs as a result of this overexcitement is believed to lead to the abnormal activation of various enzymes and impediment of neural function. Accordingly, the blockade of glutamate receptors can be thought of as a potential therapeutic approach to treat neural dysfunction associated with epilepsy.
Widely present in almost all excitatory neurons, AMPA receptors transmit signals stimulated by glutamate within the brain and are believed cukorbetegség fáj az ujjak a kezelés play a role in central nervous system diseases characterized by excess neuroexcitatory signaling including epilepsy, neurodegenerative disorders, movement disorders and pain.
At present there are no anti-epileptic drugs approved with a new mechanism that selectively blocks AMPA receptors.
If approved, perampanel will be the first in a new class of anti-epileptic drugs known as AMPA receptor antagonists. A Marketing Authorization Application MAA seeking approval of perampanel as a novel treatment for partial-onset seizures in patients with epilepsy is currently under regulatory review in the European Union EU.
Eisai also plans to conduct further studies to investigate the potential of perampanel as monotherapy for partial onset seizures and other forms of epilepsy such as Lennox Gastaut syndrome as it seeks to expand the range of approved indications for which the agent is approved.
Eisai's Commitment to Epilepsy Eisai defines epilepsy as a therapeutic area of focus, currently marketing Zonegran® under license from the originator Dainippon Sumitomo Pharma Co. By offering multiple treatment options as part of its abundant epilepsy product portfolio, Eisai will continue to make further contributions to address the diversified needs of, and increase the benefits provided to, epilepsy patients and their families.
